- FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis
- FDA approves UCB's Cimzia for ankylosing spondylitis
- FDA approves UCB's Cimzia for psoriatic arthritis
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
BRIDGEWATER, N.J. — The Food and Drug Administration has approved a generic drug for pain and inflammatory diseases made by Amneal Pharmaceuticals, Amneal said Thursday.
The FDA approved indomethacin extended-release capsules in the 75-mg strength. The drug is used to treat pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, bursitis and tendonitis.
The drug is a generic version of Merck’s Indocin. Annual sales of indomethacin ER capsules were $41.5 million during the 12-month period ended in October 2010, according to IMS Health.